{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:24:54Z","timestamp":1788042294500,"version":"build-2784847793"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant therapy (NAT) may improve resectability and survival in borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC). However, the outcomes, biomarker utility, and the impact of NAT regimens remain understudied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective analysis of PDAC patients (2004\u20132018) from three tertiary centers in Saudi Arabia. Patients who were deemed unresectable or borderline resectable at initial presentation. Analyzed variables included demographics, tumor characteristics (location, stage), NAC regimens (FOLFIRINOX, GEMCAP, gemcitabine monotherapy), response to therapy (RECIST criteria), surgical outcomes (resection rate, R0 resection), CA19\u20139 levels, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and survival outcomes (overall survival (OS) and progression-free survival (PFS)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-nine patients were eligible for the study. Median age was 60 years (range: 29\u201379 years). The study population mainly consisted of male patients (25\/39, 64%). The majority (30\/39, 80%) had a good performance status (ECOG PS 0-1). Most patients (30\/39, 77%) in the head of pancreas, while the remainder (8\/39) had it in the body or tail., Following neoadjuvant chemotherapy, 31% of patients (12\/39) had surgical resection. R0 resection was accomplished in 33% of those patients (4\/12). Surgery was associated with significantly improved median progression-free survival (PFS) compared to no surgery (19.6 vs 5.8 months; p=0.008). Certain factors, including poorer performance status, elevated CA19\u20139 levels, high NLR and PLR, and weight loss, were associated with worse PFS and OS in univariate analysis; however, these findings were not statistically significant. Multivariate analysis also suggested numerical differences in PFS and OS based on these factors, but the limited sample size likely prevented statistical significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NAT facilitates resection in approximately one-third of initially unresectable PDAC cases, with a significant improvement in PFS for patients undergoing subsequent surgery. Elevated pre-treatment CA19-9, NLR, and PLR may identify patients less likely to benefit from NAC. Biomarker-driven trials are warranted to optimize patient selection and personalize treatment strategies, especially in resource-constrained settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1756891","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:31:24Z","timestamp":1779251484000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Conversion and resection rates in borderline resectable and locally advanced pancreatic cancer following neoadjuvant therapy: a retrospective multicenter cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Ali H.","family":"Aljubran","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Cancer Center of Excellence, King Faisal Specialist Hospital and Research Centre","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaz Kamal","family":"Alata","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology, Department of Internal Medicine, Security Forces Hospital Program","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Ali","family":"Badran","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Cancer Center of Excellence, King Faisal Specialist Hospital and Research Centre","place":["Riyadh, Saudi Arabia"]},{"name":"Clinical Oncology Department, Faculty of Medicine, Ain Shams University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bader","family":"Alshamsan","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, Qassim University","place":["Qassim, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"Alnemary","sequence":"additional","affiliation":[{"name":"Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereef","family":"Elsamany","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, King Abdullah Medical City","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervat","family":"Mahrous","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Prince Sultan Bin Abdulaziz Medical City","place":["Riyadh, Saudi Arabia"]},{"name":"Faculty of Medicine, Minia University","place":["Minia, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud A.","family":"Elshenawy","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Cancer Center of Excellence, King Faisal Specialist Hospital and Research Centre","place":["Riyadh, Saudi Arabia"]},{"name":"Clinical Oncology Department, Faculty of Medicine, Menoufia University","place":["Shebin Elkom, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i32.4698","article-title":"International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: a joinpoint regression analysis","volume":"28","author":"Ilic","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2024-001544","article-title":"Current and projected incidence rates of pancreatic cancer in 43 countries: an analysis of the Cancer Incidence in Five Continents database","volume":"12","author":"Shou","year":"2025","journal-title":"BMJ Open Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1521788","article-title":"Global, regional and national burden of pancreatic cancer and its attributable risk factors from 2019 to 2021, with projection to 2044","volume":"14","author":"Li","year":"2025","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/CEG.S289269","article-title":"Epidemiology of pancreatic cancer in Saudi Arabia: a retrospective analysis of pancreatic cancer diagnosed in Saudi Arabia between 2004 and 2015","volume":"14","author":"Alghamdi","year":"2021","journal-title":"Clin Exp Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1186\/s12885-024-12401-8","article-title":"Pancreatic cancer in Saudi Arabia (2005\u20132020): increasing trend","volume":"24","author":"Elwali","year":"2024","journal-title":"BMC Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65685","article-title":"Pancreatic cancer: a retrospective study from the Najran region of Saudi Arabia","volume":"16","author":"Badheeb","year":"2024","journal-title":"Cureus"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2006.08.011","article-title":"Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy","volume":"13","author":"Varadhachary","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PloS Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8634","article-title":"Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head","volume":"26","author":"Evans","year":"2008","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00245","article-title":"Neoadjuvant treatment in pancreatic cancer","volume":"10","author":"Oba","year":"2020","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Cancer Network"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/hpb.12154","article-title":"Serum carbohydrate antigen 19\u20139 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer","volume":"16","author":"Tzeng","year":"2014","journal-title":"Hpb (Oxford)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1177\/15330338211043030","article-title":"Prognostic role of carbohydrate antigen 19 to 9 in predicting survival of patients with pancreatic cancer: a meta-analysis","volume":"20","author":"Kang","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092091","article-title":"Role of CA 19.9 in the management of resectable pancreatic cancer: state of the art and future perspectives","volume":"10","author":"Coppola","year":"2022","journal-title":"Biomedicines"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078225","article-title":"External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients","volume":"8","author":"Szkandera","year":"2013","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1159\/000527360","article-title":"Impact of preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios on long-term survival in patients with operable pancreatic ductal adenocarcinoma","volume":"31","author":"Romano","year":"2022","journal-title":"Med Princ Pract"},{"key":"B21","doi-asserted-by":"publisher","first-page":"18758","DOI":"10.1038\/s41598-020-75745-8","article-title":"Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer","volume":"10","author":"Iwai","year":"2020","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.5009\/gnl17216","article-title":"The neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are prognostic factors in patients with locally advanced pancreatic cancer treated with chemoradiotherapy","volume":"12","author":"Lee","year":"2018","journal-title":"Gut Liver"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.9285","article-title":"Preoperative platelet-lymphocyte ratio is an independent prognostic factor in ampullary carcinoma following pancreaticoduodenectomy","volume":"16","author":"Wang","year":"2018","journal-title":"Oncol Lett"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i9.2807","article-title":"Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis","volume":"21","author":"Yang","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.46254","article-title":"Pretreatment biomarkers as prognostic predictors of survival in patients with pancreatic cancer treated with gemcitabine-based therapy and 5-fluorouracil: neutrophil-to-lymphocyte ratio vs platelet-to-lymphocyte ratio","volume":"17","author":"Chen","year":"2020","journal-title":"Int J Med Sci"},{"key":"B26","volume-title":"Ajcc Cancer Staging Handbook","author":"Edge","year":"2010"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2014.02.001","article-title":"Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)","volume":"155","author":"Bockhorn","year":"2014","journal-title":"Surg (United States)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx180","article-title":"Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification","volume":"28","author":"Gilbert","year":"2017","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2023.07.005","article-title":"Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the joint meeting of the international association of pancreatology (Iap) & the Japan pancreas society (Jps) 2022 in kyoto","volume":"23","author":"Hashimoto","year":"2023","journal-title":"Pancreatology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrac010","article-title":"Prognostic relevance of the revised R status definition in pancreatic cancer: meta-analysis","volume":"6","author":"Leonhardt","year":"2022","journal-title":"Bjs Open"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13465-9","article-title":"Nationwide impact of centralization, neoadjuvant therapy, minimally invasive surgery, and standardized pathology reporting on R0 resection and overall survival in pancreatoduodenectomy for pancreatic cancer","volume":"30","author":"Augustinus","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B34","unstructured":""},{"key":"B35","unstructured":""},{"key":"B36","doi-asserted-by":"publisher","first-page":"520\u2013","DOI":"10.1200\/JCO.2022.40.4_suppl.520","article-title":"Race, sex, age, and geographic disparities in pancreatic cancer incidence","volume":"40","author":"Moshayedi","year":"2022","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrae172","article-title":"Neoadjuvant treatment versus upfront surgery in borderline resectable and resectable pancreatic ductal adenocarcinoma: meta-analysis","volume":"9","author":"Dickerson","year":"2025","journal-title":"Bjs Open"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00041","article-title":"Neoadjuvant treatment in patients with resectable and borderline resectable pancreatic cancer","volume":"10","author":"Janssen","year":"2020","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2024.100804","article-title":"Neoadjuvant treatment for pancreatic cancer: controversies and advances","volume":"39","author":"Dias e Silva","year":"2024","journal-title":"Cancer Treat Res Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2016.336","article-title":"Impact of resection margin distance on survival of pancreatic cancer: a systematic review and meta-analysis","volume":"49","author":"Kim","year":"2017","journal-title":"Cancer Res Treat"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviscsurg.2011.07.007","article-title":"Prognostic factors for resectable pancreatic adenocarcinoma","volume":"148","author":"Neuzillet","year":"2011","journal-title":"J Visc Surg"},{"key":"B43","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12885-021-08031-z","article-title":"Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial","volume":"21","author":"Janssen","year":"2021","journal-title":"BMC Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1421067","article-title":"Hallmarks of perineural invasion in pancreatic ductal adenocarcinoma: new biological dimensions","volume":"14","author":"Sun","year":"2024","journal-title":"Front Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.554502","article-title":"The key genes for perineural invasion in pancreatic ductal adenocarcinoma identified with Monte-Carlo feature selection method","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Genet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12801","article-title":"The lymph node ratio is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuvant chemotherapy","volume":"38","author":"Aoyama","year":"2018","journal-title":"Anticancer Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00066-020-01680-2","article-title":"R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007\u00b1 trial","volume":"197","author":"Fietkau","year":"2021","journal-title":"Strahlenther Onkol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.4484","article-title":"Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma","volume":"91","author":"Wagner","year":"2004","journal-title":"Br J Surg"},{"key":"B49","doi-asserted-by":"publisher","first-page":"TPS4171","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4171","article-title":"Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): a nationwide multicenter randomized controlled trial","volume":"39","author":"Janssen","year":"2021","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102970","article-title":"Stage-specific value of carbohydrate antigen 19\u20139 and carcinoembryonic antigen serum levels on survival and recurrence in pancreatic cancer: a single center study and meta-analysis","volume":"12","author":"van Manen","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1177\/1073274820977135","article-title":"Chemotherapy-induced reduction of neutrophil-to-lymphocyte ratio is associated with better survival in pancreatic adenocarcinoma: A meta-analysis","volume":"27","author":"Luo","year":"2020","journal-title":"Cancer Control"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2025.02.014","article-title":"Inflammatory markers in predicting survival in pancreatic cancer: A systematic review and meta-analysis","volume":"25","author":"Worapongpaiboon","year":"2025","journal-title":"Pancreatology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1177\/0003134821989050","article-title":"Change in neutrophil-to-lymphocyte ratio during neoadjuvant treatment does not predict pathological response and survival in resectable pancreatic ductal adenocarcinoma","volume":"88","author":"Strong","year":"2022","journal-title":"Am Surg"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20871","article-title":"Prognostic role of the pre-treatment platelet-lymphocyte ratio in pancreatic cancer: A meta-analysis","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S154162","article-title":"Prognostic value of platelet-to-lymphocyte ratio in pancreatic cancer: A comprehensive meta-analysis of 17 cohort studies","volume":"11","author":"Zhou","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B56","article-title":"Laboratory prognostic factors correspondence to independent postoperative histo-pathological prognostic factors in pancreatic ductal adenocarcinoma","volume":"25","author":"Alenezi","year":"2021","journal-title":"Medical Science"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1510016","article-title":"Survival benefits of adjuvant chemotherapy after conversion surgery in patients with advanced pancreatic cancer","volume":"14","author":"Jung","year":"2025","journal-title":"Front Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e16348","article-title":"Resectability rate of pancreatic cancer after neoadjuvant therapy","volume":"42","author":"Aljubran","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1756891\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:31:50Z","timestamp":1779251510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1756891\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":58,"alternative-id":["10.3389\/fonc.2026.1756891"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1756891","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"article-number":"1756891"}}